Colofac

Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available In Canada (English): not specified
• ATC Code: A03AA04 — Drugs for functional gastrointestinal disorders, synthetic anticholinergics, esters with tertiary amino group
• Forms & Dosages: Standard tablets 135 mg (1 tablet three times daily); Prolonged-release capsules 200 mg (1 capsule twice daily); Oral liquid formulations exist for swallowing difficulties
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: OTC in some EU/UK pharmacies for small packs; prescription-only in many countries including Australia and much of Eastern Europe/Russia; confirm status in Canada via Health Canada Drug Product Database

Critical Warnings And Restrictions In Canada

Immediate Safety Priorities, Patient Protection, And Health Canada Context

Has severe abdominal pain started suddenly or is it getting worse?

Rule out acute abdomen, bowel obstruction, ischemia or perforation before considering any antispasmodic such as mebeverine.

Stop the medicine and seek emergency care for severe abdominal pain, fever, persistent vomiting or bloody stool.

Absolute contraindications from the product monograph include hypersensitivity to mebeverine or any excipients and known paralytic ileus.

Certain formulations are contraindicated in hereditary galactose intolerance, Lapp lactase deficiency or glucose–galactose malabsorption.

Pregnancy and breastfeeding are listed as relative contraindications; avoid unless a clinician advises it after a risk–benefit discussion.

Canadian clinicians and patients must confirm market status, DIN and licensed product details through Health Canada’s Drug Product Database before prescribing or dispensing.

• Before Prescribing/Taking Colofac: allergy check, pregnancy/breastfeeding status, severe liver/kidney disease, age under 10 years.

When dispensing, pharmacists should document counselling, DIN, lot number and expiry date in the patient record.

High-Risk Groups (Elderly, Pregnant, Indigenous Health Considerations)

Elderly patients usually use standard adult dosing but exercise caution with severe hepatic or renal impairment.

Monitor elderly patients for dizziness, bradycardia and falls when starting mebeverine.

Pregnancy and breastfeeding: available data are insufficient to confirm safety in pregnancy and breastfeeding. Avoid mebeverine unless medically necessary and after a documented risk–benefit discussion.

Where possible, suggest non-pharmacological strategies and first-line conservative measures for pregnant patients.

Pediatrics: mebeverine is generally not recommended for children under 10 years; consult a paediatrician if symptoms in a child warrant antispasmodic therapy.

• Monitoring Actions: check vitals if symptomatic, review liver and renal status if severe impairment suspected, observe for allergic skin reactions.
• Cultural Safety Prompts: use culturally safe communication, involve community health workers or primary care, check local access and formulary coverage for Indigenous patients.

Interaction With Activities (Driving, Machinery, Workplace Safety Under Canadian Law)

Mebeverine adverse effects can include dizziness, tiredness and rarely visual disturbances.

Patients must be counselled not to drive or operate heavy machinery until they know how mebeverine affects them.

Workers in safety-sensitive roles should disclose medication to occupational health and follow provincial occupational health guidance.

Pharmacists should provide a written counselling note and the patient information leaflet when dispensing.

Q&A — Can I Drive After Taking It In Canada?

Short answer: Only if you feel alert and unimpaired.

If you experience dizziness, drowsiness, blurred vision or decreased pulse rate, do not drive or operate heavy machinery.

Follow provincial impaired-driving and workplace safety rules and consult your pharmacist or prescriber for job-specific advice.

Usage Basics For Canadians

INN, Brand Names Available And Canadian Context

The international nonproprietary name (INN) is mebeverine.

Colofac is the best-known international brand that contains mebeverine where marketed.

Common international packaging and strengths include 135 mg tablets and 200 mg modified‑release capsules, plus an oral liquid for swallowing difficulties.

• INN — Mebeverine
• Common Product — Colofac
• Forms — 135 mg tablet, 200 mg MR capsule, oral liquid

Legal Classification Under Health Canada (Prescription Vs OTC)

Classification varies internationally: Colofac is OTC in some EU/UK pharmacies for small packs and prescription-only in other countries.

In Canada, clinicians and pharmacists must confirm whether any mebeverine product has a Drug Identification Number (DIN) and its prescription status via Health Canada’s Drug Product Database before supply.

If a mebeverine product is not registered in Canada, importation must comply with Health Canada limited-supply rules and provincial regulations.

Canadian Dosing Guide

Standard Regimens (Health Canada Aligned Best Practice)

Typical adult dosing for IBS or gut spasm is 135 mg tablet three times daily or 200 mg modified‑release capsule twice daily.

Oral liquid preparations are used for people with swallowing difficulties.

Duration is symptomatic and may range from several weeks to months under medical supervision.

Review therapy if no benefit after approximately two weeks or if breakthrough symptoms suggest another cause.

Adjustments For Comorbidities (E.g., Diabetes)

Children under 10 years: mebeverine is generally not recommended and expert paediatric advice is required.

Elderly patients normally use standard adult dosing but monitor for dizziness and bradycardia.

Severe hepatic or renal impairment: clinical data are limited so use with caution and monitor clinically rather than relying on a formal dose reduction.

Q&A — What If I Miss A Dose Under My Provincial Drug Plan?

Clinical answer: Take the missed dose as soon as you remember unless it is almost time for the next dose; do not double up.

Administrative advice: if covered by a provincial plan such as Ontario Drug Benefit or BC PharmaCare, check repeat dispensing rules and speak with your pharmacist to avoid gaps that could interrupt therapy.

Interaction Chart (Canadian Context)

Food And Drinks (Coffee, Alcohol In Canadian Lifestyle)

No major food interactions are listed in the product monograph for mebeverine.

Alcohol may worsen gastrointestinal symptoms and increase the chance of dizziness or tiredness while taking mebeverine.

Caffeine can exacerbate bowel frequency and cramping in sensitive people.

• Avoid heavy alcohol while assessing tolerance to mebeverine.
• Monitor caffeine intake if bowel frequency worsens.
• Space dosing around meals only if the patient reports labelled GI intolerance.

Common Drug Conflicts (Refer To Health Canada Advisories)

Mebeverine shows few significant interactions in the monograph but has rare reports of causing false‑positive amphetamine urine tests.

Advise patients undergoing drug screening to notify the testing authority and their clinician.

Use provincial drug interaction tools such as Alberta Netcare or Ontario’s DPD for final local checks.

User Reports And Trends In Canada

Canadian Patient Forums And Review Platforms

Common themes from patient reports include relief of cramps and abdominal pain in many users.

Some patients report variable effects on overall bowel pattern, with mixed improvements in constipation or diarrhoea.

Occasional side effects reported on forums include dizziness and skin reactions.

Social media anecdotes are low‑quality evidence and should be verified with clinicians.

• Credibility Checklist: verify source, look for consistent reporting across users, check dates and sample size before relying on forum claims.

Community Pharmacy Feedback

Community pharmacists often see antispasmodics trialled after an IBS diagnosis is established.

Pharmacists report supply differences between brands and generics that can affect patient continuity.

Common counselling points are dosing schedules, side effects and storage advice such as storing below 25°C and keeping blister packs sealed.

Encourage active reporting of adverse events to Health Canada’s MedEffect program and provincial pharmacovigilance services.

Access And Purchase Options

National Pharmacy Chains And Point-Of-Sale Realities

Major Canadian chains generally dispense only products with a valid DIN.

If mebeverine is not currently marketed under a Canadian DIN, pharmacists will advise suitable alternatives or explain special import pathways.

• In-store purchase steps: present a valid prescription if required, pharmacist checks DIN and product labelling, counselling is provided at point of sale.
• Price-check suggestions: compare at national chains and independent pharmacies and ask the pharmacist about generics or manufacturer coupons.

In our online pharmacy, colofac is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Online Pharmacies In Canada & Provincial Restrictions

Use licensed Canadian online pharmacies only and confirm the DIN and pharmacy licence before ordering.

Importation from abroad is regulated; limited personal importation is allowed under specific Health Canada rules and must be documented by the supplying pharmacist.

• Checklist For Online Orders: verify DIN, confirm bilingual product labelling if selling in Canada, check expiry and lot number, and ensure proper storage guidance is provided.

Mechanism And Pharmacology

Simplified Patient-Friendly Explanation

Mebeverine is an antispasmodic that relaxes intestinal smooth muscle and relieves cramp-like pain.

It works locally on the gut muscle and does not display major systemic anticholinergic effects.

• Mechanism — Smooth muscle relaxation.
• Onset — Variable between patients.
• Systemic Anticholinergic Profile — Low compared with classical antimuscarinic agents.

Clinical Terms (Health Canada Monograph References)

Formulations include 135 mg immediate-release tablets taken three times daily and 200 mg modified-release capsules taken twice daily for a steadier plasma profile.

Pharmacokinetic and safety data are limited in severe hepatic or renal disease, so monitor such patients clinically.

Indications And Off-Label Uses In Canada

Approved Indications (DIN And Clinical Intent)

The primary worldwide indication is relief of abdominal pain, cramps and bowel irregularity in irritable bowel syndrome and non‑specific gut spasm.

For Canada, clinicians must confirm approved indications for any marketed mebeverine product via Health Canada and the DIN entry.

• IBS — Main indication.
• Symptomatic gut spasm — Main indication.

Common Off-Label Practices (Canadian Physicians)

Off‑label prescribing can occur for functional bowel spasm management outside strict IBS criteria.

Off‑label use requires clinical justification, informed consent and documentation in the medical record.

Adhere to contraindications and implement recommended monitoring when prescribing off‑label.

Key Clinical Findings

Canadian And International Studies 2022–2025 (Summary-Style)

Mebeverine has modest evidence for symptomatic relief of IBS-related abdominal pain and cramping.

Many clinical trials are older, but meta-analyses suggest a small-to-moderate benefit versus placebo for pain in selected patients.

• Main Outcomes — Pain reduction and improvement in cramping for some patients.
• Limitations — Heterogeneous trial methods, small sample sizes and variable endpoints.

Clinicians should check for the latest Health Canada advisories and new safety information regularly.

Ongoing Health Canada Safety Monitoring

Report adverse reactions to Health Canada’s MedEffect system to help national pharmacovigilance.

Institutions and clinicians should monitor pharmacovigilance bulletins for new safety signals such as rare allergic reactions or visual problems.

Alternatives Matrix

Comparable Medicines With DIN In Canada (Or Commonly Used Alternatives)

Pros And Cons Checklist

When choosing therapy, weigh efficacy for pain relief against side-effect profiles, contraindications and patient comorbidities.

Consider cost and provincial drug-plan coverage, and check for specific DINs before substituting brands or generics.

Common Questions From Canadian Patients

Is it habit‑forming?

No. Mebeverine is non-habit forming and can be used long-term under supervision.

How fast will it work?

Response is individual; some patients notice improvement within days while others need weeks. Reassess if no benefit after about two weeks.

Can I take it with other IBS medicines?

Usually yes, but check for additive effects and interactions with sedating drugs and opioid-induced constipation risk.

What if I have liver disease?

Use caution in severe hepatic impairment because clinical data are limited; monitor clinically rather than relying on dose reduction guidance.

• Keep the packaging and DIN for follow-up and to report adverse events.
• Seek primary care or emergency care for red flags such as fever, severe pain or bloody stool.

Coverage & Purchase Comparison Table

Comparison Table — Province/Plan, Coverage Status, Typical Patient Cost, Prescription Required

Publisher note: the table below is a placeholder and must be populated with live provincial formulary data before publication.

Step-By-Step Purchase Checklist For Canadian Patients

• Confirm DIN and exact product name before ordering.
• Verify whether a prescription is required in your province.
• Check provincial formulary coverage and eligibility.
• Compare prices at national chains and independent pharmacies.
• Ask a pharmacist about generic options, samples or special authorisation if needed.

Registration And Regulation

Health Canada Approval

Confirm whether mebeverine or Colofac has an approved Drug Identification Number (DIN) in Canada by consulting Health Canada’s Drug Product Database.

If no Canadian DIN exists, importation or private-label sources may be subject to regulatory limits and special import rules.

• Verification Steps: search the Health Canada Drug Product Database, check the manufacturer licence and confirm the DIN before supply.

DIN Number And Labelling Requirements

Canadian labelling must meet bilingual requirements and include DIN, manufacturer, strength, dosage form, expiry and storage instructions such as store below 25°C and protect from moisture and light.

Pharmacists must ensure labelling and counselling meet their provincial College standards when dispensing.

Storage And Handling

Standard Canadian Household Conditions

Store mebeverine in the original blister packaging below 25°C (77°F) and protect it from moisture and light.

Keep the medicine out of reach of children and do not use after the expiry date on the pack.

• Avoid storing in humid places such as bathrooms.
• Keep blister packs intact until use.
• Return unwanted medicines to a pharmacy for safe disposal.

Cold-Chain Requirements (Where Applicable)

Standard mebeverine formulations do not require cold-chain storage.

For imported or special supplies, verify storage and transport instructions and document chain-of-custody when the pharmacy receives the shipment.

Guidelines For Proper Use

Canadian Pharmacist Guidance (Practical Counselling Points)

Confirm the diagnosis of IBS versus organic disease before recommending mebeverine.

Check absolute contraindications such as paralytic ileus and hypersensitivity, and screen for hereditary carbohydrate intolerance where relevant.

Review the full medication list for interactions and check for drugs that cause sedation or bradycardia.

Counsel on dosing: 135 mg three times daily or 200 mg MR twice daily, and missed-dose rules: take when remembered and do not double up.

Report adverse events to Health Canada and document patient education in the record.

• Verify pregnancy and breastfeeding status.
• Assess the need for specialist referral if red flags are present.
• Document DIN, lot and expiry when dispensing.

Provincial Health Authority Recommendations

Align with provincial protocols for IBS management, which usually include dietary measures, fibre advice, peppermint oil and psychological therapies where indicated.

Include mebeverine as part of a multimodal plan if clinically appropriate and ensure follow-up.

Provide live links to provincial formularies and guidelines in the final published article for up-to-date coverage information.

Delivery Across Canada (English)